PRKAA1 and colorectal carcinoma: Given that AMPK is commonly inhibited in various pathophysiological conditions such as obesity and diabetes, which are known risk factors for CRC, targeting AMPK could be a promising strategy for mitigating intestinal tumorigenesis.